Alnylam RNAi Therapies
Select below to explore educational, scientific, and clinical resources related to the therapeutic areas in which Alnylam therapies are used. Information on investigational products or unlicensed indications is not included on this website.
UK healthcare professionals seeking further details may contact Alnylam Medical Information, where enquiries will be handled in accordance with UK Medical Information requirements. All material in this section is provided for scientific and educational purposes only.
Our RNAi Therapies
Access AMVUTTRA® (vutrisiran) Therapy Page
AMVUTTRA® 
(vutrisiran)
Explore clinical and educational resources related to the use of vutrisiran in adult patients with hereditary transthyretin amyloidosis with stage 1 or stage 2 polyneuropathy (hATTR-PN) or wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Access ONPATTRO® (patisiran) Therapy Page
ONPATTRO® (patisiran)
Explore clinical and educational resources related to the use of patisiran in adult patients hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with stage 1 or stage 2 polyneuropathy.
Access GIVLAARI® (givosiran) Therapy Page
GIVLAARI® (givosiran)
Explore clinical and educational resources related to the use of givosiran in adult patients and adolescents aged 12 years and older with acute hepatic porphyria (AHP).
Access OXLUMO® (lumasiran) Therapy Page
OXLUMO® (lumasiran)
Explore clinical and educational resources related to the use of lumasiran in patients in all age groups with primary hyperoxaluria type 1 (PH1).
